- Home
- SF vs PCVX Comparison
SF vs PCVX Comparison
Compare SF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SF | PCVX |
|---|---|---|
| Founded | 1890 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 6.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SF | PCVX |
|---|---|---|
| Price | $128.71 | $48.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $130.00 | $101.67 |
| AVG Volume (30 Days) | 794.0K | ★ 1.5M |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 2.14 | N/A |
| EPS | ★ 5.66 | N/A |
| Revenue | ★ $5,293,276,000.00 | N/A |
| Revenue This Year | $13.43 | N/A |
| Revenue Next Year | $11.00 | N/A |
| P/E Ratio | $22.53 | ★ N/A |
| Revenue Growth | ★ 11.76 | N/A |
| 52 Week Low | $73.27 | $27.66 |
| 52 Week High | $133.08 | $93.77 |
Technical Indicators
Market Signals| Indicator | SF | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 59.27 |
| Support Level | $124.67 | $42.40 |
| Resistance Level | $128.75 | $45.15 |
| Average True Range (ATR) | 2.98 | 1.94 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 65.59 | 91.30 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial Corp is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its world-wide wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.